Chronic lymphocytic leukemia (CLL) cells extensively interact with and depend on their
surrounding tumor microenvironment (TME). The TME encompasses a heterogeneous array …

Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a
standard therapy for chronic lymphocytic leukemia (CLL), delivering high complete …

Venetoclax, a BH3 mimetic, is a novel targeted anti-cancer drug with a unique mechanism of
action leading to the execution of apoptosis through inhibition of the Bcl-2 protein. The …

Targeted therapies such as venetoclax (VEN)(Bcl-2 inhibitor) have revolutionized the
treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL …

Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has
improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early …

The introduction of BTK inhibitors and BCL2 antagonists to the treatment of chronic
lymphocytic leukemia (CLL) has revolutionized therapy and improved patient outcomes …

Simple Summary Novel targeted agents in chronic lymphocytic leukemia (CLL) are
employed with different strategies. The evolution of response assessment criteria of the …

Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution—thanks to the
discovery of crucial pathogenic mechanisms. CLL is still an incurable disease due to …

B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically
Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL). A …

Simple Summary Targeting BCL-2 through venetoclax is an effective therapy for a series of
hematological cancers, such as mantle cell lymphoma (MCL), but resistance to venetoclax is …